Abstract-Experimental
D
espite contemporary medical treatments, heart failure remains a major cause of morbidity and mortality in developed countries. 1 Transplantation of stem or progenitor cells is a promising strategy for cardiac repair, attracting tremendous attention of basic scientists and clinicians. 2 Several issues have been raised against harvesting human embryonic stem cells. 3 Compared with embryonic stem cells, autologous adult stem cells do not raise any major ethical or immunologic problems. Sources of adult stem cells include the muscle, bone marrow, blood, epidermis, brain, liver, and, more recently, the adipose tissue. 4 Chronologically, skeletal myoblasts were the first to be used clinically in patients with ischemic heart disease. 5 Experimental studies have shown that injected myoblasts stably engraft into postinfarction scars and improve left ventricular function. Current hypotheses of mechanisms of myoblasts actions include limitation of left ventricular remodeling, as well as paracrine effects determining angiogenesis, recruitment of resident quiescent cardiac cells, and extracellular matrix stabilization. 6 However, the skeletal muscle, as well as the skin, brain, liver, and bone marrow, are essential organs. Cell harvesting procedures from these organs are painful and costly, and frequently associated with the risk of donor-site tissue morbidity. For instance, bone marrow aspiration may yield low numbers of stem cells on processing, which necessitates an ex vivo expansion step to obtain sufficient cell numbers for clinical application. Therefore, research interest has increased toward alternative sources of stem cells. Adipose tissue may represent an ideal source of autologous stem cells, because it is easy to obtain with minimal patient discomfort, but yet capable of yielding cell numbers substantial enough to obviate extensive expansion in culture. 4 The stem cell population derived from the collagenasedigested human adipose tissue (stromal-vascular fraction [SVF] ) has been shown to differentiate into multiple cell lineages, including the adipose tissue, cartilage, bone, 4,7-9 skeletal muscle, 10 neuronal cells, 11, 12 endothelial cells, [13] [14] [15] [16] cardiomyocytes, [17] [18] [19] [20] [21] [22] and smooth muscle cells. [23] [24] [25] [26] There is much confusion in the literature when using terms describing multipotent stem cells from the adipose tissue stroma. We refer here to the term adipose tissue-derived stromal cells (ADSCs), which identifies a plastic-adherent cell population that includes vascular (pericytes and endothelial progenitor cells)/adipocyte progenitor cells (preadipocytes) and adult multipotent mesenchymal stem cells (MSCs), besides circulating blood cells, fibroblasts, endothelial cells, smooth muscle cells, and immune cells, such as macrophages and lymphocytes 27 (Figure 1 ). ϩ cells in the SVF derived from the adipose tissue. 13 The most likely reason for these discrepancies is that the latter investigations were performed by the use of limitedly cultured ADSCs (primary culture of 3 days with no subsequent plating). Flow cytometric analysis showed that the CD34 ϩ cell subset is constituted of 2 populations: the CD34 ϩ /CD31 ϩ cells and the CD34 ϩ / CD31 Ϫ cells. 14 Quantitative analysis of laser-Doppler data revealed a time-dependent increase in blood flow after the injection of CD34 ϩ /CD31 Ϫ cells in the ischemic hind limb. 14 Comparison between the angiogenic activity of the SVF from the adipose tissue with that from the bone marrow demonstrated that the administration of 1ϫ10 6 SVF cells enhanced neovascularization to a similar extent as that of 1ϫ10 6 bone marrow-derived mononuclear cells (BM-MNCs). 13 Likewise, it has been found that cells positive for the kinase insert domain receptor (KDR; alternative names: vascular endothelial growth factor [VEGF] receptor-2 [VEGFR-2], protein tyrosine kinase receptor Flk-1, CD309 antigen) isolated from cultured ADSCs featured an endothelial phenotype in the presence of VEGF. 15 The vascularized adipose tissue does contain other types of cells, such as pericytes, dendrytic cells, macrophages, microvascular endothelial cells, and may also contain bone marrow-derived mesenchymal stem cells. 4, 29 Disruption of the blood supply during fat tissue isolation may result in the release of circulating bone marrow-derived mesenchymal stem cells and pericytes, known to possess the potential for multi-lineage differentiation. 30 -32 It is therefore plausible that ADSC-induced vessel formation and growth might also be related to the contribution of resident microvascular endothelial cells or preadipocytes through the secretion of proangiogenic factors, 33, 34 or through the contribution of periendothelial pericytes capable of interacting with and stabilizing endothelial networks. 35 Based on these observations, pericytes may represent a second angiogenic precursor, resident in the adult human adipose tissue, with similar angiogenic potency to-but phenotipically distinct from-ADSCs. Recent reports have also demonstrated that human ADSCs themselves express pericyte lineage markers and exhibit perivascular functions, by showing increased migration in response to vascular endothelial growth factor (VEGF)-165 and platelet-derived growth factor (PDGF)-BB, a pericytelike morphology around microvessels, and contributing to augmented microvascular density during angiogenesis by migrating toward vessels. 36 These observations have supported the hypothesis that ADSCs themselves might originate from perivascular stem cells, similarly to pericytes. 32 This hypothesis is intriguing but awaits confirmation through future studies.
Characterization of Adipose
ADSCs have been shown to exhibit also in vitro differentiation into the cardiomyocyte lineage. [17] [18] [19] [20] [21] [22] In these reports, different methods for the induction of differentiation have been used. Rangappa et al first described the appearance of beating cells on treatment of mesenchymal stem cells isolated from rabbit subcutaneous adipose tissue with 5-azacytidine. 17 At 2 weeks, 30% of the cells aggregated and formed a ball-like structure with spontaneous contractile activity. 17 We subsequently described the spontaneous cardiomyocyte differentiation of ADSCs from primary cultures of ADSCs isolated from murine visceral and subcutaneous adipose tissue, without any chemical treatment. 16, 21 In such latter protocols, the percentage of beating clones counted at 20 days ranged from 0.02% to 0.07% of the plated ADSCs. Electrophysiological studies revealed a pacemaker activity of the cells. 18 These data indicate the presence of myogenic stem cells in the adipose tissue stroma.
Characterization of Culture-Expanded Adipose Tissue-Derived Stromal Cells for Multipotency
In a nondifferentiating medium, culture-expanded cells (until passage 4) isolated from the bone marrow (bone marrowderived stromal cells [BMSCs] ) and from the adipose tissue (ADSCs) have been shown to give rise to apparently homogeneous populations with similar cell size and cell surface markers. 37 Both populations were shown to express CD13, CD29 (␤1-integrin), CD44, CD58, CD90, CD105 (endoglin), and CD166. SH-3, an epitope present on CD73 (ecto-5Ј-nucleotidase), and STRO-1, a marker for cells with multilineage potential, are also uniformly expressed by both ADSCs and BMSCs. 38 However, the expression of adhesion molecules with known functions in regulating the homing or the mobilization of stem cells differs between these 2 cell preparations. For example, ADSCs express CD48d (␣ 4 -integrin, which forms a heterodimer with CD29 to create very late activation antigen-4, VLA-4, the main cognate ligand for vascular cell adhesion molecule-1 [VCAM-1] CD106 ligand), whereas cells derived from the bone marrow do not. The pattern of expression of VCAM-1 is reversed. 37 Similarly, ADSCs express high levels of CD54 (intercellular adhesion molecule-1 [ICAM-1]), whereas BMSCs have very low expression of this molecule. This is an intriguing observation, given the important role of the interaction between these adhesion molecules and their ligands in regulating stem cell trafficking. 37 Still, overall, the general pattern of mesenchymal lineage differentiation of ADSCs and BMSCs in nondifferentiating media is very similar. More differences have, however, been observed when cells are grown in differentiating media. In particular, in an osteogenic differentiation medium alkaline phosphatase activity is significantly greater in ADSCs compared with BMSCs, whrereas mineralization is more extensive with BMSCs. Both cell populations express mRNAs specific for type-I collagen, osteocalcin, osteonectin, osteopontin, bone morphogenetic protein (BMP)-1, parathyroid hormone receptor, retinoic acid-X receptor(RXR)␣, vitamin D, and core-binding factor alpha (CBFA)-1, a transcription factor that regulates multiple osteogenic genes. 4 Thus, environmental factors appear to play an important role in ADSC differentiation into a given cell lineage.
Advantages of Adipose Tissue-Derived Stromal Cells Over Other Cell Sources
Studies using human bone marrow cell transplantation in ischemic patients suggest that human angiogenic cell therapy requires the administration of at least 10 7 to 10 9 endothelial progenitor cells (EPCs) from peripheral blood or umbilical cord, depending on the degree of stem cells purity and the delivery method. The rarity of these progenitors in peripheral blood has implications for the large amounts of patient's blood required to achieve a proangiogenic or a proneovasculogenic effect. Such amounts are not easily available in a clinical setting. In a comparative study between peripheral blood and the adipose tissue we compared the yield of endothelial progenitor cells from the adipose tissue and peripheral blood. 16 We found that the adipose tissue is capable of yielding higher number of endothelial progenitor cells than peripheral blood. Furthermore, in a comparative study of BMSCs and ADSCs obtained from the same donors, De Ugarte et al demonstrated that ADSCs required approximately 5% the cell number used for marrow cells to reach initial confluence by 1 week. 37 This suggests a larger proliferative potential for ADSCs, either for properties intrinsic to the cells or as the result of the higher density of stem cells within the initial population. Thus, assuming clinical equivalence, the higher proliferative activity of the adipose tissuederived population would generate a clinically effective cell dose more rapidly than for bone marrow cells.
Recent studies have also reported on the in vivo and in vitro immunoregulatory properties of ADSCs. Independent studies from different laboratories have shown that cultureexpanded human ADSCs (ie, cells beyond passage (P)0), as opposed to freshly isolated SVF cells or early-passage ADSCs, reduce their expression of surface histocompatibility antigens and no longer elicit allospecific T-cell proliferative responses. 39, 40 If confirmed by further independent and comprehensive testing, such differences would highlight the possibility for ADSCs, limitedly to culture-expanded cells from allogeneic healthy donors, to serve as a valuable source of stem cells for therapeutic use in older patients, 41, 42 or in those with malignant diseases, or obese, 43 who cannot yield sufficient numbers of functional ADSCs, in alternative to autologous cells.
We cannot, however, avoid taking into account also other factors coming into play when using the adipose tissue as a stem cell source for clinical transplantation. Because the enzymatic digestion of the adipose tissue with collagenase represents a critical step in ADSCs isolation, parameters such as the digestion time and enzyme activity, playing a role in the isolation procedure of primary ADSCs, may also have a significant effect on cell yield, viability, phenotype, and differentiation potential. 44 In addition, the digestion process increases the risk of contamination. The challenge is to isolate the maximum possible number of functional progenitors without damaging the cell population in the process and in conformity with standards of good manufacturing practice. Careful testing of collagenase purity, lot-to-lot variation, and the purity of cell preparations from contaminants appear therefore to be mandatory before embarking in human clinical trials.
Altogether, the yield (a therapeutic dose of CD34 ϩ -enriched cells with angiogenic activity can be isolated in approximately 1-hour digestion of a limited amount of adipose tissue, without cell culture expansion) and safety from immune rejection in case of allogeneic administration from healthy donors appear major theoretical advantages of adipose tissue as an alternative to other sources of cells for myocardial repair.
Outcome Findings
The administration of cells from the adipose tissue can favorably affect revascularization in animal models of ische- 17, 18, 20 smooth muscle cells, and endothelial cells 13, 14 ; (3) secretion of antioxidant chemicals, free radical scavengers, and chaperone/heat shock proteins at the site of ischemia. 14 In this context, the study by Miyahara et al 20 is of special interest, because it showed the capability of adipose tissuederived MSCs to improve left ventricular function mainly by growth factor-mediated paracrine effects. The presence of cardiomyocytes within the MSC grafts appeared to be rare, and the authors therefore concluded that MSCs acted mainly through paracrine pathways to trigger angiogenesis.
A further mechanism by which implanted ADSCs can improve heart function is the recruitment of native cardiac resident stem or progenitor cells by paracrine mechanisms. 56 ADSCs would modulate the "stem cell niche" of the host by stimulating the recruitment of endogenous stem cells to the implantation site and promoting their differentiation along the required lineage pathway. Excess production or degradation of the cardiac extracellular matrix (ECM) can lead to progressive ventricular dilatation and cardiac dysfunction. By determining or favoring a balance between ECM degradation and production through the secretion of growth factors, implanted cells may stabilize the ventricular scaffold and therefore exert beneficial effects on the adverse remodeling 57 (Figure 2 ). All such hypotheses need further testing.
An interesting additional possibility currently being explored is to enhance the angiogenic and myogenic effects of transplanted ADSCs by modifying them ex vivo (ie, by tranfection before implantation) to express one or more selected genes. Rehman et al sought to enhance the angiogenic effects of cell transplantation through the overexpression of VEGF and basic fibroblast growth factor (bFGF). 33 Subsequently, Zhu et al reported that the intravenous injection of human ADSCs transfected with the gene for HGF resulted in greater angiogenesis and improved cardiac function compared with unmodified cells. 58 These studies have consistently demonstrated that cell-based angiogenic gene therapy results in greater angiogenesis and functional improvement than cell transplantation alone. The promising results of these early studies need to be thoroughly confirmed before running attempts at the clinical application of this concept.
Despite several unsettled mechanistic issues, the (still relatively modest, in our opinion) bulk of animal studies has been deemed convincing enough for some researchers to with acute myocardial infarction for a minimum of 2 and a maximum of 12 hours from onset to a percutaneous coronary intervention (PCI), and unresponsive to nitroglycerin; (2) a successful revascularization of the culprit lesion in the major epicardial vessel; (3) an area of hypoor akinesia corresponding to the culprit lesion; (4) left ventricular ejection fraction in a range between 30% and 50% at the time of successful revascularization; and (5) the ability to undergo liposuction. For the PRECISE trial inclusion criteria are: (1) coronary artery disease not amenable to any type of revascularization (percutaneous or surgical) in the target area; (2) hemodynamic stability; and (3) the ability to undergo liposuction.
Certainly more clinical studies are needed to demonstrate the long-term efficacy of this approach.
Perspectives and Open Questions
Although several studies have provided in vitro and in vivo evidence that ADSCs contain a population of adult multipotent mesenchymal stem cells with therapeutical potential for repairing damaged cardiac tissues, a number of fundamental points need to be addressed before this approach can be proposed clinically. Because the majority of patients with acute myocardial infarction undergo spontaneous or therapeutic reperfusion, the ability of ADSCs to improve cardiac function should be tested in an infarcted reperfused myocardium. The literature is replete with examples of therapies that work in the presence of a permanent coronary occlusion. Consequently, it is of utmost importance to determine whether ADSCs are effective when coronary occlusion is followed by reperfusion, an event that dramatically alters the milieu of the myocardial interstitium and of the myocardium itself. Second, improvement in left ventricular function has been shown when stem cells are injected intramyocardially in the periinfarcted area. Clinically, the most practical route for ADSC administration is the intravascular (intracoronary) delivery, but only a limited number of studies have explored this modality of administration. A recent study by Valina et al has shown that the intracoronary administration of ADSCs into the acutely infarcted myocardium allows ADSCs to transdifferentiate into endothelial and vascular smooth muscle cells, leading to an improvement of left ventricular function, remodeling, and perfusion in a porcine model. 49 These observations have been confirmed in subsequent studies, showing that, after injection into the periinfarcted region, the administration of these cells improves left ventricular ejection fraction, with postmortem evidence of reduced fibrosis and increased angiogenesis. 50 Other investigators have demonstrated substantial improvement of left ventricular ejection fraction in a chronic rat model of myocardial infarction after the intramyocardial injection of ADSCs. 51 The main mechanism whereby ADSCs improve cardiac function (differentiation into cardiac cells versus fusion versus paracrine effects on preexisting cells) remains poorly understood, and the advantage of using total unfractionated ADSCs compared with purified populations of ADSCs, such as the CD34 ϩ -purified ADSCs, remains to be determined. Although it is tempting to jump on clinical application, we advocate much more experimental work in animal models. Large animal models of myocardial infarction, such as in swine, exist, closely resemble human disease, but are laborious and expensive. Yet such models should guide to the proper selection of cell types, timing, and mode of delivery before running the risk of throwing this entire promising area of research into discredit for premature clinical trials. 
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